NOTICE OF MAILING CHANGE
☐ Check here if you wish to discontinue receiving this publication.

☐ Check here if your address has changed and you wish to continue receiving this publication. Make corrections below and mail this page to:

NIH Guide
Printing & Reproduction Branch
National Institutes of Health
Room B4BN08, Building 31
Bethesda, Maryland 20892

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

OFFICIAL BUSINESS
Penalty for Private Use, $300

The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 18, No. 38
October 27, 1989
NOTICES

NEI INSTITUTIONAL TRAINING GRANTS ........................................... 1
National Eye Institute
Index: EYE

DATED ANNOUNCEMENTS (RFPs AND RFAs)

LARGE BOWEL ADENOMATOUS POLYP DIETARY INTERVENTION STUDY--
CLINICAL CENTERS (RFP) ...................................................... 1
National Cancer Institute
Index: CANCER

SUPPORT FOR "EMERGING TECHNOLOGY": STUDIES ON THE AUGMENTATION OF
CELLULAR AND HUMORAL IMMUNE FUNCTION TO INCREASE THE PROTECTIVE
IMMUNE RESPONSE TO HIV INFECTION (RFP) ................................. 2
National Cancer Institute
Index: CANCER

REAGENTS AND/OR SERVICES FOR AIDS VACCINE RESEARCH (RFP) ............ 2
National Cancer Institute
Index: CANCER

STUDIES USING PRIMATES AND OTHER ANIMALS FOR AIDS VACCINE RESEARCH (RFP) .... 3
National Cancer Institute
Index: CANCER

NATIONAL CANCER INSTITUTE COOPERATIVE HUMAN TISSUE NETWORK (RFA) ............... 4
National Cancer Institute
Index: CANCER

ONGOING PROGRAM ANNOUNCEMENTS

NUTRITION RESEARCH AND ORAL HEALTH ........................................ 5
National Institute of Dental Research
Index: DENTAL RESEARCH

NEUROSCIENCE RESEARCH ON DRUG ABUSE ........................................ 7
National Institute on Drug Abuse
Index: DRUG ABUSE
NOTICES

NEI INSTITUTIONAL TRAINING GRANTS
P.T. 44; K.W. 0720005, 1014002

National Eye Institute

The National Eye Institute has recently revised its supplemental instructions for institutional National Research Service Award applications. NEI has only one receipt date for these applications: January 10 of each year.

Investigators are strongly encouraged to obtain a copy of these revised instructions before submitting applications for the January 10, 1990 receipt date. Please contact:

Ralph J. Helmsen, Ph.D.
Research Training and Resources Officer
National Eye Institute
National Institutes of Health
Building 31, Room 6A46
Bethesda, Maryland 20892
Telephone: (301) 496-5884

DATED ANNOUNCEMENTS (RFPs AND RFAs)

LARGE BOWEL ADENOMATOUS POLYP DIETARY INTERVENTION STUDY--CLINICAL CENTERS

RFP AVAILABLE: NCI-CN-05220-20
P.T. 04; K.W. 0715035, 0705025, 0710095, 0755015

National Cancer Institute

The National Cancer Institute, Division of Cancer Prevention and Control, is soliciting proposals for clinical centers to conduct a large bowel adenomatous polyp dietary intervention study. This multi-center randomized controlled intervention study will examine the effect of a low-fat, high-fiber, vegetable and fruit-enriched diet on the recurrence of adenomatous polyps of the large bowel. It is expected that an individual offeror will randomize participants at a minimum rate of 7 per month, or 170 participants over the two-year randomization period. General requirements include identification and accrual of eligible participants, nutritional education and counselling, participant follow-up and endpoint assessment. Intermediate endpoint specimens will be collected. Data maintenance and reporting quality control systems will be supported. A separate Request for Proposals (RFP) will be issued for a data and nutrition coordinating center.

Date of issuance of the RFP will be approximately October 26, 1989, with a closing date for receipt of proposals to be approximately January 4, 1990. The Institute plans to award up to 12 contracts from this solicitation.

Copies of RFP No. NCI-CN-05220-20 may be obtained by sending a WRITTEN request to:

Mr. Charles E. Lerner, Contract Specialist
National Institutes of Health
National Cancer Institute
Research Contracts Branch, PCGS
Executive Plaza South, Room 635
Bethesda, Maryland 20892
Telephone: (301) 496-8603
SUPPORT FOR "EMERGING TECHNOLOGY": STUDIES ON THE AUGMENTATION OF CELLULAR AND HUMORAL IMMUNE FUNCTION TO INCREASE THE PROTECTIVE IMMUNE RESPONSE TO HIV INFECTION

MASTER AGREEMENT ANNOUNCEMENT AVAILABLE: NCI-CP-95666-45

P.T. 34; K.W. 0745045, 0715008, 0760080, 0740023

National Cancer Institute

The National Cancer Institute, Division of Cancer Etiology is soliciting proposals from offerors with the capability to conduct Studies on the Augmentation of Cellular and Humoral Immune Function to Increase the Protective Immune Response to HIV Infection. The successful offeror must be able to develop procedures for immune therapy in HIV-infected human subjects with purified HIV proteins and/or recombinant vector expressing HIV proteins.

The offeror must obtain consent and human subject protection certification; furnish information on protocols used and results obtained; and provide samples or serum and/or cells from the immunized subjects to NCI upon request.

It is anticipated that a Master Agreement Award will be made FOR A PERIOD OF FORTY-EIGHT (48) MONTHS. MASTER AGREEMENTS CONSIST OF A POOL OF PREQUALIFIED OFFERORS. After award, groups of Master Agreement holders will be invited to propose competitively on Master Agreement Orders that will be designed to accomplish a specific task to be designated by the Government.

Master Agreement announcement No. NCI-CP-95666-45 for the task described above will be available to interested offerors on approximately October 21, 1989. Responses will be due approximately 30 days after the publication date of this announcement. Copies of this RFP may be obtained by sending a written request to:

Opal J. Bailey
Contract Specialist
Cancer Etiology Contract Section, Research Contracts Branch
National Cancer Institute
Executive Plaza South, Room 620
Bethesda, Maryland 20892

REAGENTS AND/OR SERVICES FOR AIDS VACCINE RESEARCH

MASTER AGREEMENT ANNOUNCEMENT AVAILABLE: NCI-CP-95664-45

P.T. 34; K.W. 0715008, 0740075, 0780005, 0755041, 0755045, 0760060

National Cancer Institute

The National Cancer Institute, Division of Cancer Etiology, is soliciting proposals from offerors with the capability to conduct Studies on Tasks A through H listed below or on any combination thereof. Separate, complete proposals are required for each task.

Task A: Protein Purification; Immunological Services, and Virus Detection and Isolation.
Task B: Virus Production.
Task C: DNA Sequencing.
Task D: Molecular Cloning; Production of Recombinant HIV, SIV, and/or EIAV proteins; Production of recombinant vaccinia virus.
Task E: Peptide Synthesis.
Task F: Immunological Assays and Virus Characterization.
Task G: PCR Analysis.
Task H: Pathology.

It is anticipated that a Master Agreement Award will be made for a period of forty-eight (48) months. Master Agreements consist of a pool of prequalified offerors. After award, groups of Master Agreement holders will be invited to propose competitively on Master Agreement Orders that will be designed to accomplish a specific task designated by the Government.

Master Agreement announcement No. NCI-CP-95664-45 for the tasks described above will be available to interested offerors approximately October 21, 1989. Responses will be due approximately 30 days after the publication date of this announcement.
STUDIES USING PRIMATES AND OTHER ANIMALS FOR AIDS VACCINE RESEARCH

MASTER AGREEMENT ANNOUNCEMENT AVAILABLE: NCI-CP-95665-45

P.T. 34; K.W. 0715008, 0740075, 1002002

National Cancer Institute

The National Cancer Institute, Division of Cancer Etiology, is soliciting proposals from offerors with the capability to conduct Task A, B, C-1, C-2 or any combination listed below. Separate proposals are required for each task or subtask.

Task A: Provide non-human primates and, housing, care and health surveillance for these primates; immunize primates with SIV, HV-1 or HV-2 vaccines (to be provided by NCI); infect primates with HIV or SIV vaccines and assess the status of these immunized and infected primates; and conduct other experiments.

Task B: Provide, house, and care for severe combined immunodeficient (SCID) mice; reconstitute these animals with human tissue to obtain lymphoid and/or cells which can be infected with HIV in the mice; develop methods to reconstitute the mice with human immune cells; evaluate various antibodies; and, if suitable systems are developed, conduct immunization in the human-SCID mice and assess the response.

Task C-1: Provide other animals and house and care for them; infect animals with virus; determine the immune response; and re-isolate virus from tissues of infected animals.

Task C-2: Provide animals for immunogenicity studies; house and care for these animals; immunize these animals, immunize these animals with candidate vaccines; and provide NCI with sera and cells from immunized animals.

The offeror's facilities must conform to the standards for animal care outlined in the Guide for care and Use of Laboratory Animals as published in the DHHS publication Number (NIH 85-23) or superseding editions.

It is anticipated that a Master Agreement Award will be made for a period of forty-eight (48) months. Master Agreements consist of a pool of prequalified offerors. After award, groups of Master Agreement holders will be invited to propose competitively on Master Agreement Orders that will be designed to accomplish a specific task to be designated by the Government.

Master Agreement Announcement No. NCI-95665 for the tasks described above will be available to interested offerors on approximately October 21, 1989. Responses will be due approximately 30 days after the publication date of this announcement.

Copies of the RFP may be obtained by sending a written request to:

Opal J. Bailey
Contract Specialist
Cancer Etiology Section
Research Contracts Branch
National Cancer Institute
Executive Plaza South, Room 620
Bethesda, Maryland 20850
NATIONAL CANCER INSTITUTE COOPERATIVE HUMAN TISSUE NETWORK

RFA AVAILABLE: 90-CA-01

P.T. 34, FF, II; K.W. 0780000, 0780020, 0715035

National Cancer Institute

Letter of Intent Receipt Date: January 12, 1990
Application Receipt Date: April 25, 1990

The Diagnosis Research Program of the Division of Cancer Biology and Diagnosis at the National Cancer Institute (NCI) invites applications for Cooperative Agreements from institutions capable of and interested in participating in The Cooperative Human Tissue Network. The purpose of this established network is to collect and distribute human tumor tissue and normal tissue to stimulate research. The Network was developed in response to a growing need by researchers for improved access to human tumor tissue. Basic and developmental studies in many areas of cancer research, including molecular biology, immunology and genetics, have been encouraged by improved access to tissue. Hundreds of investigators have taken advantage of the existence of the Network and thousands of tissues have been distributed since the inception of the Network in January 1987. The NCI plans expand the Network from three institutions to four or five institutions.

The existing Network has already demonstrated the feasibility of the network approach and the continuing need of researchers for access to human materials. Systems have been developed that allow efficient communication among laboratories regarding tissue requests and availability. The Network is not a tissue bank, but rather responds to investigator requests to meet existing tissue requirements on a current basis. Applicants may plan for limited storage of rare tumors that would otherwise not be available. Special consideration will be given to ensuring access to and nationwide distribution of rare pediatric tumor specimens.

Awards will be made as cooperative agreements which create an assistance relationship with substantial involvement of NCI staff during the performance of the project, as outlined in this request for applications (RFA). This mechanism is used when the NCI wishes to stimulate investigator interest and proposes to advise or assist in an important and opportune area of research. The NCI anticipates making four or five awards for project periods of five years. Although this project is provided for in the financial plans of the NCI, the award of cooperative agreements pursuant to the RFA is contingent on the availability of funds appropriated in fiscal year 1991.

Inclusion of women and minorities are encouraged. If they are excluded, reasons for this exclusion must be included in the application.

This RFA is a one-time solicitation with a specified deadline of April 25, 1990, for receipt of applications.

The RFA label available in the 10/88 revision of Application Form 398 must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of your application such that it may not reach the review committee in time for review. In addition, the RFA number and title should be typed on line 2 of the face page of the application form.

A copy of the complete RFA describing eligibility criteria, the research goals and scope, the cooperative agreement mechanism, the review criteria and the method of applying should be obtained before beginning the application process. Copies of the complete RFA can be obtained from:

Roger L. Aamodt Ph.D.
Program Director for Pathology and Cytology
Diagnosis Program
Division of Cancer Biology and Diagnosis
National Cancer Institute
Executive Plaza South, Room 638
6120 Executive Boulevard
Rockville, Maryland 20892
Telephone: (301) 496-7147

Inquiries concerning this RFA are encouraged and should be directed to Dr. Aamodt at the address or telephone number listed above.

This program is described in the catalog of Federal Domestic Assistance no 13.394, Cancer Detection and Diagnosis Research. Awards are under authorization of the Public Health Service Act, Title IV, Part A (Public Law...
78-410 as amended: 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

ONGOING PROGRAM ANNOUNCEMENTS

NUTRITION RESEARCH AND ORAL HEALTH

P.T. 34; K.W. 0710095, 0715148, 0755020, 0785055, 0710030

National Institute of Dental Research

The National Institute of Dental Research (NIDR) encourages submission of high quality applications for the support of research and research training on the influence of diet and nutrition on oral health and disease, salivary gland function, craniofacial development, osteoporosis as related to craniofacial structures, and wound healing in order to expand its activities in these and other related areas. Appropriate studies might encompass basic research, development of animal models, epidemiological studies, and clinical studies of special population groups, including the aged and minorities and those in foreign countries which present special research opportunities.

BACKGROUND

The oral cavity and associated structures are the sites of disease (e.g., dental caries, periodontal disease, herpes, salivary gland disorders, oral cancer) and congenital anomalies (such as cleft lip and palate) that may relate to nutritional status. It is also evident that nutrients interact with physiologic systems in the oral cavity such as host and microbial cell replication mechanisms, host cell repair mechanisms and immune response mechanisms in such a manner as to increase or decrease the risk of disease and influence tissue development. Thus, the oral tissues and associated structures constitute a major site of interactions between nutritional factors and physiological systems, a relationship that makes oral health no less vulnerable to the effects of nutrition than general health.

Expansion of the NIDR Nutrition Research Program was recommended by expert panels on Long-Range Research Plans for the 1990's, at a recent Workshop on International Collaboration for Oral Research, and by the Dental Research Programs Advisory Committee (PAC) at its November 1988 meeting. The PAC recommended the issuance of a Program Announcement to encourage the needed research and training in this area.

RESEARCH GOALS

The objective of this announcement is to solicit applications for research grants and individual research training to elucidate the role of diet and nutrition in the development and maintenance of oral and craniofacial tissues and in the prevention of oral diseases. Projects concerning nutrition and oral health and disease as related to minorities, women, and the elderly and to populations in developing countries which present special research opportunities (via international collaboration) are encouraged. Examples of research projects are:

- Influence of nutrient-drug interactions on specific salivary gland structure and functions in the elderly.
- Relationship between nutrient intake during critical periods of gestation and susceptibility to craniofacial anomalies.
- Effect of malnutrition on abnormal tooth development or on osteoporosis of the jaw bone.
- Effect of sugar substitutes and food additives on the physiology of cariogenic bacteria and on dental caries.
- Bioavailability and mineralized tissue effects of fluoride in nutritionally compromised individuals.
- Preventive role of antioxidant nutrients in diseases of the periodontium or of the oral mucosa.

The above list is not intended to describe the full range of possible activities to be supported nor to direct applicants to these areas. Applicant institutions are encouraged to focus on their areas of greatest strength.
The announcement is also intended to: encourage increased collaboration among the various disciplines of dental research involving nutrition and among basic and clinical scientists; encourage training of basic and clinical research scientists in oral nutrition; and expedite the translation of advances in nutrition/oral biology research into new and improved methods for patient care.

MECHANISMS OF SUPPORT

Support for this program will be through regular research project grants (R01), program project grants (R01), small grants (R03), FIRST awards (R29), AREA awards (R15), career development awards (K04, K11, K15), and postdoctoral fellowships (F32, F33). Receipt dates and policies that govern research grant programs of the National Institutes of Health will prevail.

APPLICATION AND REVIEW PROCEDURES

Applications in response to this announcement will be reviewed on a nationwide basis in competition with other applications and in accordance with NIH peer review procedures. Review criteria include: the significance and originality of the research goals and approaches; feasibility of the research and adequacy of the experimental design; training, experience, research competence, and dedication of the investigator(s); adequacy of available facilities and availability of appropriate study populations; provisions for the protection of human subjects and humane care of animals; and appropriateness of the requested budget relative to the work proposed. Applicants are encouraged to include women and minorities in clinical and epidemiological studies. For studies which exclude women or minorities, a clear rationale for exclusion should be provided.

Funding decisions will be based on the Study Section's and the National Advisory Council's recommendations regarding scientific merit and program relevance, and on the availability of appropriated funds.

Inquiries concerning this announcement should be addressed to Dr. Joseph E. Ciardi at the address given below. The specific application forms and kits required to respond to this announcement are available from the institution's Office of Research and Sponsored Programs or from the Division of Research Grants, NIH. Applications will be accepted on an indefinite basis in accordance with the receipt dates specified in the pertinent application kits.

The phrase "NIDR PA: NUTRITION RESEARCH AND ORAL HEALTH" should be typed on line 2 of the face page of the application form PHS 398 (rev. 10/88) or on line 3 of the fellowship application form PHS 416 (rev. 7/88). The original and six copies should be sent or delivered to:

Grants Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, Maryland 20892-4500

For further information concerning this announcement and the mechanisms of support for research and training available in this connection, applicants are encouraged to contact:

Joseph E. Ciardi, Ph.D.
Program Administrator
Caries, Restorative Materials
and Salivary Research Branch
Extramural Program
National Institute of Dental Research
Westwood Building, Room 505
Bethesda, Maryland 20892-4500
Telephone: (301) 496-7884

This program is described in the Catalog of Federal Domestic Assistance No. 13.121, Diseases of the Teeth and Supporting Tissues. Awards will be made under authorization of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241); and administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review.
NEUROSCIENCE RESEARCH ON DRUG ABUSE

P.T. 34; K.W. 1002030, 0404009, 0705055, 0760075, 0414005, 0404000, 0785115

National Institute on Drug Abuse

This Program Announcement was published in the NIH Guide for Grants and Contracts on October 20, 1989, Vol. 18, No. 37, however, it was inadvertently omitted in the Table of Contents. The Announcement is being repeated in its entirety.

PURPOSE

The purpose of this announcement is to encourage and stimulate investigator interest in broad areas of neuroscience research relevant to the problem of drug abuse. Many research tools are now available to allow for major advances in understanding the neurobiology of drug abuse to determine the effects of drugs on the structure and function of the nervous system. These include new histochemical and autoradiographic procedures, light and electron microscopic analysis, imaging and analytic techniques applicable to living tissue (e.g., PET, MRI), and various neurophysiological and neuropharmacological techniques, especially those monitoring neural processes during ongoing behavior (e.g., single-cell electrophysiology, in vivo microdialysis and voltammetry, evoked potentials, EEG). As a final part of this initiative, The National Institute on Drug Abuse (NIDA) expects that an increased understanding of the relationship between brain anatomy, physiology, and pharmacology and drug abuse behaviors will increase the capacity to design appropriate therapeutic pharmaceautical void of abuse liability and its consequences, and develop drug therapies for correcting neurochemical imbalances created by the abuse of drugs. Additionally, investigations into the neural basis of drug seeking should identify those neurobiological factors that make an individual vulnerable to the abuse of drugs.

RESEARCH OBJECTIVES

The neuroscience program of the NIDA's Division of Preclinical Research encourages investigations into the basic mechanisms underlying the action of abused drugs and substances on the central nervous system as well as research leading to the development of drugs that potentially may be used on the relationship between drug-receptor interactions or neurochemical alterations and consequences of drug usage in terms of behavioral processes is specifically encouraged. Areas of particular interest include the following:

1. Brain Reward Mechanisms in Drug Abuse
2. Neuropsychopharmacology of Abused Drugs
3. Anabolic Steroid Abuse
4. Drug-Induced Neurotoxicity
5. Developmental Neurobiology
6. Drug Effects on Cognitive Processes
7. Drug Effects on Sensory Processes
8. Blood-Brain Barrier Studies
9. Clinical Neuroscience

Support can be obtained in the form of R01 (Research Project Grants), R03 (Small Grants), R13 (Research Conference Grants), and R29 (First Independent Research Support and Transition Awards).

NIMH and various NIH Institutes have specific programs in the neurosciences. Grant applications will be assigned to the appropriate Institute based upon existing programmatic guidelines.

ELIGIBILITY

Applications may be submitted by public or private nonprofit or for-profit organizations such as universities, colleges, hospitals, laboratories, units of State or local governments, and eligible agencies of the Federal government. Women and minority investigators are encouraged to apply.

APPLICATION PROCEDURES AND RECEIPT SCHEDULE

State and local government agencies may use form PHS 5161-1 (rev. 11/88). All other applicants should use the research grant application from PHS 398 (rev. 10/88). The title of this announcement "NEUROSCIENCE RESEARCH ON DRUG ABUSE" should be typed in item number 2 on the face page of the PHS 398 application form or in item 9 on the PHS 5161-1.

Application kits containing the necessary forms and instructions may be obtained from business offices or offices of sponsored research at most...
universities, colleges, medical schools, and other major research facilities. If such a source is not available, the following office may be contacted for the necessary application material: Grants Management Branch, NIDA, Parklawn Building, Room 10-25, 5600 Fishers Lane, Rockville, Maryland 20857.

Applications received under this announcement will be assigned to an initial review group (IRG) in accordance with established PHS Referral Guidelines. The IRGs, consisting primarily of non-Federal scientific and technical experts, will review the applications for scientific and technical merit. Notification of the review recommendations will be sent to the applicant after the initial review.

Applications will receive a second-level review by an appropriate National Advisory Council whose review may be based on policy as well as scientific merit considerations. Only applications recommended for approval by the advisory council may be considered for funding.

The signed original and six (6) permanent, legible copies of the completed application (original and two copies, if using PHS 5161-1) should be sent to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, Maryland 20892

Receipt of Applications Initial Advisory Council Earliest
Review Review Start Date
February 1 June/July Sept/Oct December 1
June 1 Oct/Nov Jan/Feb April 1
October 1 Feb/March May/June July 1

Applications submitted in response to this Announcement are not subject to the intergovernmental review requirements of Executive Order 12372, as implemented through Department of Health and Human Services regulations at 45 CFR Part 100 and are not subject to Health Systems Agency review.

REVIEW CRITERIA

Criteria for scientific/technical merit review of regular research grant applications will include the following: significance and originality from a scientific and technical standpoint of the goals of the proposed research; adequacy of the methodology proposed to carry out the research; qualifications of the Principal Investigator and other key research personnel; availability of adequate facilities, other resources, and collaborative arrangements necessary for the research, appropriateness of budget estimates for the proposed research activities, and adequacy of provisions for the protection of human subjects and welfare of animals subjects as applicable.

FURTHER INFORMATION

Further information and consultation on program requirements relevant to neuroscience research inquiries can be obtained from:

Dr. Roger Brown
Neuroscience Research Branch
National Institute on Drug Abuse
Parklawn Building, Room 10A-31
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-6975

FOOTNOTE: This program is described in the catalog of Federal Domestic Assistance No. 13.279. Grants will be awarded under the authority of Section 301 of the Public Health Service Act, as amended (42 USC 241) and administered in accordance with the PHS Grants Policy Statement and Federal regulations at 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD BUILDING IS: 5333 Westbard Avenue
Bethesda, Maryland 20816